Towards a better mucolytic.
作者信息
Dickey Burton F, Evans Christopher M
机构信息
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
出版信息
Eur Respir J. 2023 May 25;61(5). doi: 10.1183/13993003.00619-2023. Print 2023 May.
Abstract
摘要
相似文献
1
Towards a better mucolytic.
Eur Respir J. 2023 May 25;61(5). doi: 10.1183/13993003.00619-2023. Print 2023 May.
2
[Controlled study of mucolytic agent associated with kinesitherapy in obstructive lung diseases (author's transl)].
Acta Tuberc Pneumol Belg. 1973 Jan-Feb;64(1):74-9.
3
Aerosolized detergents and mucolytic agents in the treatment of stable chronic obstructive pulmonary disease.
Am Rev Respir Dis. 1974 Dec;110(6 Pt 2):104-10. doi: 10.1164/arrd.1974.110.6P2.104.
4
Thiolated polyglycerol sulfate as potential mucolytic for muco-obstructive lung diseases.
Biomater Sci. 2024 Aug 20;12(17):4376-4385. doi: 10.1039/d4bm00381k.
5
A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
Eur Respir J. 2023 May 25;61(5). doi: 10.1183/13993003.02022-2022. Print 2023 May.
6
The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine.
Ann N Y Acad Sci. 1963 Mar 30;106:298-310. doi: 10.1111/j.1749-6632.1963.tb16647.x.
7
[Mucolytic agents. Polycentric study of a carbocysteine-sobrerol combination].
Arch Monaldi Mal Torace. 1989 Jul-Dec;44(4-6):791-3.
8
A new mucolytic, bromhexine ("bisolvon"). A double-blind study.
Med J Aust. 1971 May 1;1(18):963-5. doi: 10.5694/j.1326-5377.1971.tb87967.x.
9
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Cochrane Database Syst Rev. 2015 Jul 29(7):CD001287. doi: 10.1002/14651858.CD001287.pub5.
10
Evaluation of a new mucolytic drug.
Clin Pharmacol Ther. 1974 Jul;16(1):58-62. doi: 10.1002/cpt1974161part158.
引用本文的文献
1
The impact of Tanreqing injection on mucus hypersecretion and cough in bronchiectasis: A meta-analysis of randomized controlled trials.
Medicine (Baltimore). 2024 Nov 8;103(45):e40465. doi: 10.1097/MD.0000000000040465.
2
Emerging cell and molecular targets for treating mucus hypersecretion in asthma.
Allergol Int. 2024 Jul;73(3):375-381. doi: 10.1016/j.alit.2024.04.002. Epub 2024 May 1.
本文引用的文献
1
A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
Eur Respir J. 2023 May 25;61(5). doi: 10.1183/13993003.02022-2022. Print 2023 May.
2
Airway Mucus Dysfunction in COVID-19.
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1304-1306. doi: 10.1164/rccm.202207-1306ED.
3
Mucus-targeting therapies of defective mucus clearance for cystic fibrosis: A short review.
Curr Opin Pharmacol. 2022 Aug;65:102248. doi: 10.1016/j.coph.2022.102248. Epub 2022 Jun 8.
4
Mucus concentration-dependent biophysical abnormalities unify submucosal gland and superficial airway dysfunction in cystic fibrosis.
Sci Adv. 2022 Apr;8(13):eabm9718. doi: 10.1126/sciadv.abm9718. Epub 2022 Apr 1.
5
Inhibition of calcium-triggered secretion by hydrocarbon-stapled peptides.
Nature. 2022 Mar;603(7903):949-956. doi: 10.1038/s41586-022-04543-1. Epub 2022 Mar 23.
6
Physiology and pathophysiology of human airway mucus.
Physiol Rev. 2022 Oct 1;102(4):1757-1836. doi: 10.1152/physrev.00004.2021. Epub 2022 Jan 10.
7
Airway Epithelial Innate Immunity.
Front Physiol. 2021 Nov 26;12:749077. doi: 10.3389/fphys.2021.749077. eCollection 2021.
8
Disulfide disruption reverses mucus dysfunction in allergic airway disease.
Nat Commun. 2021 Jan 11;12(1):249. doi: 10.1038/s41467-020-20499-0.
9
Muco-Obstructive Lung Diseases.
N Engl J Med. 2019 May 16;380(20):1941-1953. doi: 10.1056/NEJMra1813799.
10
Emerging Concepts and Therapies for Mucoobstructive Lung Disease.
Ann Am Thorac Soc. 2018 Nov;15(Suppl 3):S216-S226. doi: 10.1513/AnnalsATS.201806-368AW.
Zotero 插件